Abstract
From 1985 to 1991, 9 patients with endometrioid carcinoma of the ovary were treated and followed at the University of Ancona, Department of Gynecology and Obstetrics. Four patients (44.4%) had Stage I disease, 1 (11.1%) Stage II, 1 (11.1%) Stage III and 3 (33.3%) Stage IV. Six patients (66.6%) had grade 2 of the disease and 3 (33.3%) grade 3. Two of the patients (22.2%) had synchronous endometrial carcinoma while 3 had histologic evidence of endometriosis at the time of presentation. All the patients received treatment of combination of surgery, polychemotherapy, hormone and/or immunotherapy. The overall survival rate after a median follow up of 26.6 months was 66.6%. A high survival (100%) was observed for patients with associated endometriosis.
MeSH terms
-
Adenocarcinoma* / drug therapy
-
Adenocarcinoma* / mortality
-
Adenocarcinoma* / surgery
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carboplatin / administration & dosage
-
Cisplatin / therapeutic use
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Endometriosis* / drug therapy
-
Endometriosis* / mortality
-
Endometriosis* / surgery
-
Epirubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Follow-Up Studies
-
Humans
-
Medroxyprogesterone / administration & dosage
-
Middle Aged
-
Neoplasm Staging
-
Ovarian Neoplasms* / drug therapy
-
Ovarian Neoplasms* / mortality
-
Ovarian Neoplasms* / surgery
-
Retrospective Studies
-
Survival Rate
-
Tamoxifen / administration & dosage
Substances
-
Tamoxifen
-
Epirubicin
-
Etoposide
-
Cyclophosphamide
-
Carboplatin
-
Medroxyprogesterone
-
Cisplatin